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Abstract: PNH is a rare clonal disorder of hematopoietic stem cells, therefore all blood cells lineages are involved. The main
feature is an increased sensitivity of erythrocytes to complement-mediated cell lysis due to deficiency of membrane-bound
GPI (glycosylphosphatidylinositol)-anchored proteins which normally function as inhibitors of reactive hemolysis. In the
present study, we performed flow cytometric analysis using monoclonal antibodies against CD55 and CD59 for the detection
of PNH-type clone in the blood of 50 patients (28 females and 22 males, age range 7-67 yrs). In one patient only we found a
large population (95%) of granulocytes with decreased expression of both CD55 and CD59 molecules (type I PNH) and in two
others with partial loss of CD55 expression (type II PNH). The expression was determined chiefly on granulocytes which in
the control group showed reliable and high expression of CD55 and CD59.
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Introduction
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare
acquired hematological disorder characterized by ane-
mia, intravascular hemolysis, bone marrow hypoplasia,
as well as tendency to thrombosis and infection. Incre-
ased sensitivity of erythrocytes to complement-media-
ted cell lysis is due to deficiency of membrane-bound
GPI (glycosylphosphatidylinositol)-anchored proteins
which normally function as the inhibitors of reactive
hemolysis [7, 17]. GPI-anchored proteins include: com-
plement regulatory proteins like DAF (decay accelera-
ting factor, CD55), MIRL (membrane inhibitor of
reactive lysis, CD59), and other membrane proteins
participating in immune function (CD14, CD16, CD24,
CD48, CD58, CD66b, CD67) [4, 12, 13, 15]. PNH is a
clonal disorder of hematopoietic stem cells and all blood
cell lineages are involved. Disturbances of GPI-ancho-
red proteins are commonly due to somatic mutation of
the phosphatidyloinositol glycan complementation class
A (PIG-A) gene [9]. The mutation can be either sponta-
neous or facilitated by some conditions [7]. The coexi-
stence of multiple clones with different mutations of
PIG-A gene in the same PNH patient has been also
reported. Apart from mutation there is also a survival
advantage of the PNH clone [1,10]. Dominance of PNH
clone is probably due to negative selection against the
non-mutated cells rather than positive selection of the
PIG-A gene mutant cells [3, 10]. In PNH patients, usu-
ally coexist normal and deficient subpopulations of cells
with regard to GPI-anchored protein expression. PNH-
phenotype has been also described in various hematolo-
gical  disorders , such as aplastic  anaemia,
myelodysplastic syndromes, myeloproliferative and
lymphoproliferative syndromes like acute non-lymp-
hoblastic leukemias, non-Hodgkin‘s lymphomas, Hodg-
kin‘s disease and acute lymphoblastic leukemias [10, 12,
15, 18]. Various tests are used for the determination of
PNH. Routine diagnostics involves: the Ham’s test (aci-
dified serum lysis test) and the sugar water yeast (suc-
rose hemolysis) test but both determine only the
sensitivity of red blood cells to complement-mediated
lysis. For the evaluation of reduced expression of GPI-
anchored proteins on all blood cells, flow cytometric
analysis is probably the best method to date [13,14]. In
the present study, using monoclonal antibodies against
CD55 and CD59 and flow cytometry, we searched for
PNH-type clone in the blood of patients with clinical
symptoms suggesting PNH.
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Materials and methods
Patients. We studied 50 patients (28 females, 22 males, aged 7 to 67
years) clinically suspected for PNH, diagnosed at the Department of
Haematological and Haemopoietic Proliferative Diseases and De-
partment of Child Infectious Diseases of University of Medical
Sciences, Poznan, Poland. This group clinically manifested hemoly-
tic anaemia, in some patients accompanied by hematuria, abdominal
pain and signs of persistent infection, most commonly of the uroge-
nital tract. Five control subjects were healthy (blood donors).
Detection of PNH-type cells. Five mililiters of peripheral blood was
collected from antecubital vein to a tube with EDTA anticoagulant.
One-hundred microliter blood samples were immunostained in tubes
with the following two-color combinations of monoclonal antibodies
(Becton Dickinson): isotype control mAbs and anti-CD45
FITC/CD14 PE, anti-CD3 FITC/CD19 PE, anti-CD4 FITC/CD8 PE,
anti-CD3 FITC/CD16+56 PE mAbs for determination of main sub-
populations of leukocytes.
For the detection of PNH-type granulocytes, monocytes and
lymphocytes we used fluorescein-isothiocyanate (FITC)-labeled an-
ti-CD55 (clone IA10) and phycoerythrin (PE)-labeled anti-CD59
(clone p282, H19) monoclonal antibodies (Becton Dickinson). 
The cells were incubated with antibodies at room temperature for
15 min in the dark, then a 2-mL volume of FACS-lysing solution
(Becton Dickinson) diluted 1:10 was added to each tube, gently
mixed, and incubated for further 10 min in the dark. The tubes were
washed twice with PBS and centrifuged at 1200 × g for 4 min. The
white cell pellets were resuspended in 0.5 mL PBS and analyzed by
flow cytometry using a FACScan flow analyzer and CellQuest
software (Becton Dickinson). At least 20 × 103 events were collected.
Expression of CD55 and CD59 molecules was quantified by the
determination of mean fluorescence intensity (MFI).
Results and discussion
In the group of patients with the suspicion of PNH,
alterations of expression of CD55 and CD59 were found
in 3 patients only. In two patients, partial depletion of
the above-mentioned markers (so-called type II, Fig. 1)
was established, while in one a total loss of both antigens
was evident (so-called type I, Fig. 2) [14]. The criterion
of recognition of cell clone showing absence of both
markers was the detection of cell subset (above 5% of
cells) in which there was a fall of expression of both
antigens, at least 1 log MFI. Population of phagocytes
(neutrophils and monocytes) was considered as the most
suitable for the evaluation of CD55 and CD59 expres-
sion. For cytometric analysis only such cells were selec-
ted which in terms of FSC/SSC (size, cell granularity)
showed features of living, undamaged and not apoptotic
cells. In the control group (healthy blood donors), there
was no alteration in the expression of CD55 and CD59
on phagocytic cells (Fig. 3). 
The results of this study show that PNH is rather rare
disorder in spite of clinical suspicions. We were able to
confirm PNH diagnosis in only 3 patients out of 50
tested, what corresponded to 6% of cases.
We analyzed the expression of two GPI-anchored
proteins CD55 and CD59. Both are regarded as the most
valuable diagnostic markers of PNH [6, 12, 19]. CD59
is probably the most important protein, protecting the
cell from the complement-dependent lysis [17].
According to Hsi [8], it is necessary to evaluate both
markers because the assessment of only one antigen
(CD59) provides false positive results in blood donors.
Other members of GPI complex such as CD67, CD48,
CD24 and CD16 are also considered as markers of PNH
[17], but their use for detection of the disease-specific
cell clone is less common.
Expression of CD55 and CD59 may be determined
on all blood cells such as leukocytes, erythrocytes and
platelets [17]. We have chosen the population of phago-
cytes (both granulocytes and monocytes) as relatively
durable during laboratory processing. Erythrocytes sho-
wing deficit of GPI proteins are known to be hemolyzed
easily, what makes the detection of searched clone dif-
ficult [12, 13]. Alternatively one can assess reticulocy-
tes, because this cell subset is usually increased in
patients with PNH and shows higher resistance to hemo-
lysis than mature red blood cells [4]. According to
Oelschlagel et al. [12], the optimal approach appears to
be a simultaneous evaluation of both erythrocytes and
granulocytes for the expression of CD55 and CD59. This
is possible with the use of commercial kits REDQUANT
and CELLQUANT for assessment of the respective cell
subsets.
Detection of the cell clone possessing PNH phenoty-
pe may be facilitated by the application of monoclonal
antibodies against CD11b and glycophorin in concert
with CD55 and CD59. This approach provides better
gating of the appropriate subpopulations [18]. Another
possibility for better definition of negative clones could
be to determine separate cell subsets based on Laser
Scanning Cytometry, new technology combining capa-
bilities of flow cytometry and morphology [5] or to
assess distribution and density of target molecules [16].
In this study, the presence of negative cell population
above 5% was adopted as a criterion for recognition of
the PNH cell clone. Cell acquisition was 20 × 103.
According to Wang et al. [18], using sensitive flow
cytometry and acquisition of 105 cells one can accept the
presence of >0.003% cells within CD11b+ cells (granu-
locytes) as a PNH clone. It may explain confirmation of
PNH diagnosis in three patients only within the cohort
of 50 patients. Such low number of positive cases may
be also due to in vivo lysis of cells showing altered
expression of GPI complex and problems with the de-
tection of single cells.
It is worth to remember that the clone with features
of PNH can be found in the blood of patients with myelo-
or lymphoproliferative disorders [7, 11]. Moreover, the
presence of CD55-negative and CD59-negative cell clo-
ne (most commonly only one marker is lacking) is
considered to be a good prognostic factor in myelodys-
plastic syndromes. This is manifested by lower tendency
to progression towards acute leukemia, less karyotypic
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Fig. 2. Scattergram A shows almost absence of CD55 and CD59 expression on backgated (scattergram B) monocytes and granulocytes in
patient with type I PNH. Scattergram C represents isotype control.
Fig. 1. Scattergram A shows partial loss of CD59 expression on backgated (scattergram B) monocytes and granulocytes in patient with type
II PNH. Scattergram C represents isotype control.
Fig. 3. In comparison to PNH, monocytes and granulocytes (scattergram B) shows uniform and full expression of CD55 and CD59 antigens
on all cells in healthy individual. Scattergram C represents isotype control.
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disturbances and better response for cyclosporin treat-
ment. It is supposed that the presence of PNH clone in
the course of myelodysplastic syndrome suggests milder
damage of the bone marrow [7].
To summarize, cytometric evaluation of CD55 and
CD59 antigens in the population of blood granulocy-
tes/monocytes permits rapid confirmation of diagnosis
of paroxysmal nocturnal hemoglobinuria, at least in
those patients in which complement-dependent cell lysis
is relatively low. Moreover, this assay may add to mo-
nitoring and prognosis in patients with myelo- and lym-
phoproliferative disorders.
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